Evidence map›Paper›PMID 39220526›Full record

ArticleACS omega2024

Jolanta Pulit-Prociak, Olga Długosz, Anita Staroń, Dominik Domagała, Krzysztof Pociecha, Mikołaj Grabowski, Michał Zielina, Marcin Banach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jolanta Pulit-ProciakFaculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.ORCID https://orcid.org/0000-0001-5005-7134
Olga DługoszFaculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.
Anita StarońFaculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.
Dominik DomagałaFaculty of Food Technology, University of Agriculture in Krakow, Balicka 122, Cracow 30-149, Poland.
Krzysztof PociechaFaculty of Pharmacy, Jagiellonian University, Medyczna 9, Cracow 30-688, Poland.
Mikołaj GrabowskiFaculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.
Michał ZielinaFaculty of Environmental Engineering and Energy, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.
Marcin BanachFaculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, Cracow 31-155, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In today's medicine, progress often depends on new products with special qualities. Nanotechnology focuses on the creation of materials tailored to fulfill specific therapeutic requirements. This study aims to elucidate the potential of nanoparticles, particularly titanium dioxide nanoparticles, as carriers for pharmaceutical agents. To mitigate the release of potentially harmful titanium ions from the carrier's surface, modifications were implemented. In the initial phase, titanium dioxide, nanoparticles were obtained based on the sol-gel method, and their surfaces were coated with galactose. Characterization of these materials encompassed analysis of the particle size, specific surface area, microscopic morphology, and titanium ion release. Additionally, drug release profiles, particularly those of tadalafil, were investigated.

Identifiers

PMID39220526
PMCPMC11360011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.